INKT

Business Context and Reporting Period

MiNK Therapeutics, Inc. (INKT) is a clinical-stage biopharmaceutical company developing allogeneic, off-the-shelf invariant natural killer T (iNKT) cell therapies for cancer and immune-mediated diseases. This Form 10-K covers the fiscal year ended December 31, 2024. The company operates as a non-accelerated filer, smaller reporting company, and emerging growth company. Its lead product candidate, agenT-797, is in Phase 1 and Phase 2 trials for solid tumors and viral acute respiratory distress syndrome (ARDS). The company maintains significant operational and financial ties with Agenus Inc., which owns approximately 55% of MiNK's common stock.

Key Financial Metrics

Note: The company has no revenue. Margins are not applicable due to zero revenue.

Material Changes vs. Prior Period

• Expense Reduction: Total operating expenses decreased by approximately 50% year-over-year, driven by a 59% reduction in R&D expenses and a 42% reduction in G&A expenses. This was primarily due to decreased headcount, lower share-based compensation, and a $1.8 million gain from the forgiveness of previously recorded liabilities.
• Financing Activity: In May 2024, the company raised approximately $5.8 million through a private placement of common stock. In March 2024, it issued a $5.0 million convertible promissory note to Agenus Inc.
• Stock Structure: On January 28, 2025, the company executed a 1-for-10 reverse stock split to regain compliance with Nasdaq listing rules regarding minimum bid price and market value of listed securities.
• Going Concern: The independent auditor included an explanatory paragraph regarding substantial doubt about the company's ability to continue as a going concern, citing recurring losses and a net capital deficiency.

Outlook, Risks, and Management Commentary

• Clinical Progress: Management highlighted encouraging data for agenT-797 in solid tumors (durable disease stabilization) and viral ARDS (70%+ survival in ventilated patients vs. 10% control). A Phase 2 investigator-sponsored trial for gastric cancer is actively enrolling. Preclinical data for engineered programs MiNK-215 and MiNK-413 were presented at major conferences in 2024.
• Liquidity: As of December 31, 2024, cash balances were $4.6 million. Management believes this, combined with anticipated funding from corporate transactions, is sufficient for more than one year. However, the company explicitly states it will require additional funding to continue operations and may need to seek equity or debt financing, strategic partnerships, or non-dilutive grants.
• Risks: Key risks include the failure of clinical trials, inability to raise additional capital, dependence on Agenus for administrative services and funding, and the novelty of the iNKT cell platform which may face regulatory hurdles. The company also faces potential delisting risks if it fails to maintain Nasdaq compliance.
• Unusual Items: The 2024 financials include a $1.8 million gain from liability forgiveness and a $0.6 million expense related to the change in fair value of the related party note.

Investor Verification Checklist

• Capital Runway: Verify the status of "anticipated funding from corporate transactions" mentioned in the liquidity section to confirm the one-year runway assumption.
• Related Party Dependence: Review the terms of the $5.0 million note to Agenus and the intercompany services agreement to understand potential conversion triggers and ongoing cost allocations.
• Stock Split Impact: Confirm the post-split share count and trading status following the January 2025 1-for-10 reverse stock split.
• Clinical Enrollment: Monitor enrollment rates for the Phase 2 gastric cancer trial and the ARDS platform trial, as patient recruitment is a stated risk factor.
• Going Concern Status: Assess whether the company has secured the additional funding necessary to avoid the "substantial doubt" qualification in future filings.